Murase T, Kuriyama M, Maeda S, Ando Y, Itoh H, Watanabe H
Tokai Urological Cancer Registry.
Hinyokika Kiyo. 1996 Sep;42(9):639-43.
In 39 hospitals in the Tokai region of Japan, 815 cases with prostatic cancer were registered between 1988 and 1991, 91 of which (13.3%) were diagnosed as stage A. Eighty cases of stage A cancer were subclassified into stage A1 (33 cases) or stage A2 (47 cases). A detailed investigation was performed on these 80 subclassified cases with respect to tumor markers, treatment methods and prognosis. The tumor marker, prostate specific antigen (PSA) was positive in 18.5% of the A1 cases and 53.8% of the A2 cases. Endocrine therapy was administered in 45.5% of the A1 and 78.7% of the A2 cases. There was 1 (3.0%) case of progression in the stage A1 group, and 2 cases in stage A2 group. The 5-year survival rate was 97.0% for stage A1 and 88.6% for stage A2. The prognosis of prostatic cancer in stage A was fairly good in both the A1 and A2 subclasses in our series.
在日本东海地区的39家医院中，1988年至1991年间登记了815例前列腺癌病例，其中91例（13.3%）被诊断为A期。80例A期癌症被进一步细分为A1期（33例）或A2期（47例）。对这80例细分病例在肿瘤标志物、治疗方法和预后方面进行了详细调查。肿瘤标志物前列腺特异性抗原（PSA）在18.5%的A1期病例和53.8%的A2期病例中呈阳性。45.5%的A1期病例和78.7%的A2期病例接受了内分泌治疗。A1期组有1例（3.0%）病情进展，A2期组有2例。A1期的5年生存率为97.0%，A2期为88.6%。在我们的系列研究中，A1和A2亚类的A期前列腺癌预后都相当好。
